| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer | EVP & CFO
3 companies
Ryan D Maynard is Chief Financial Officer at TVRD and has filed Form 4s across 3 companies. Ryan D Maynard's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $77K at current prices.
Historically, Ryan D Maynard's trades have earned a strong insider score of 75/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +66.3%.
The biggest single holding is IOVA (~$66K) as Director. The IOVA filings lean toward selling, a net 42,500 shares.
Ryan D Maynard has 27 Form 4 filings on record from January 2015 to June 2026, across 4 companies: Director at Iovance Biotherapeutics (IOVA), 2015–2026; Chief Financial Officer at Foghorn Therapeutics (FHTX), 2026; Chief Financial Officer at Tvardi Therapeutics (TVRD), 2022–2024, and 1 more.
The 31 reported transactions were 24 option or other derivative awards, 3 open-market sales, 2 option exercises and 1 stock award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $51K and 3 sales worth about $896K.
The only open-market purchase was 7,500 shares of IOVA at an average $6.75 on May 31, 2022, about $51K. Twelve months later IOVA was up 29%.
The largest open-market sale was 50,000 shares of IOVA at an average $10.06 on November 12, 2024, about $503K. Twelve months later IOVA was down 74%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | IOVA Iovance Biotherapeutics, Inc. | Director | Sale+OE | 50,000 | $10.06 | $503,000.00 | -87.0% | -45.1% | -73.8% | |
| Feb 8, 2023 | TVRD Tvardi Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 5,488 | $0.53 | $2,908.64 | -40.7% | -64.2% | -95.5% | |
| May 31, 2022 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 7,500 | $6.75 | $50,587.50 | New | +58.5% | +29.5% | |
| Nov 3, 2017 | RIGL Rigel Pharmaceuticals Inc | EVP & CFO | Sale+OE | 100,000 | $3.90 | $390,000.00 | - | - | - |